Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release

Madhukar H. Trivedi, David L. Dunner, Susan G. Kornstein, Michael E. Thase, John M. Zajecka, Anthony J. Rothschild, Edward S. Friedman, Richard C. Shelton, Martin B. Keller, James H. Kocsis, Alan Gelenberg

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.

Original languageEnglish (US)
Pages (from-to)420-429
Number of pages10
JournalJournal of Affective Disorders
Volume126
Issue number3
DOIs
StatePublished - Nov 2010

Fingerprint

Social Adjustment
Placebos
Self Report
Leisure Activities
Quality of Life
Major Depressive Disorder
Therapeutics
Major Depressive Disorder 2
Venlafaxine Hydrochloride
Long-Term Care
Health Surveys
Motivation
Outpatients
Depression
Recurrence
Surveys and Questionnaires

Keywords

  • Maintenance treatment
  • Major depressive disorder
  • Psychosocial outcomes
  • Venlafaxine extended release

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. / Trivedi, Madhukar H.; Dunner, David L.; Kornstein, Susan G.; Thase, Michael E.; Zajecka, John M.; Rothschild, Anthony J.; Friedman, Edward S.; Shelton, Richard C.; Keller, Martin B.; Kocsis, James H.; Gelenberg, Alan.

In: Journal of Affective Disorders, Vol. 126, No. 3, 11.2010, p. 420-429.

Research output: Contribution to journalArticle

Trivedi, MH, Dunner, DL, Kornstein, SG, Thase, ME, Zajecka, JM, Rothschild, AJ, Friedman, ES, Shelton, RC, Keller, MB, Kocsis, JH & Gelenberg, A 2010, 'Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release', Journal of Affective Disorders, vol. 126, no. 3, pp. 420-429. https://doi.org/10.1016/j.jad.2010.04.011
Trivedi, Madhukar H. ; Dunner, David L. ; Kornstein, Susan G. ; Thase, Michael E. ; Zajecka, John M. ; Rothschild, Anthony J. ; Friedman, Edward S. ; Shelton, Richard C. ; Keller, Martin B. ; Kocsis, James H. ; Gelenberg, Alan. / Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. In: Journal of Affective Disorders. 2010 ; Vol. 126, No. 3. pp. 420-429.
@article{724f71049a9f4c4aafd0cb7895244107,
title = "Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release",
abstract = "Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.",
keywords = "Maintenance treatment, Major depressive disorder, Psychosocial outcomes, Venlafaxine extended release",
author = "Trivedi, {Madhukar H.} and Dunner, {David L.} and Kornstein, {Susan G.} and Thase, {Michael E.} and Zajecka, {John M.} and Rothschild, {Anthony J.} and Friedman, {Edward S.} and Shelton, {Richard C.} and Keller, {Martin B.} and Kocsis, {James H.} and Alan Gelenberg",
year = "2010",
month = "11",
doi = "10.1016/j.jad.2010.04.011",
language = "English (US)",
volume = "126",
pages = "420--429",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release

AU - Trivedi, Madhukar H.

AU - Dunner, David L.

AU - Kornstein, Susan G.

AU - Thase, Michael E.

AU - Zajecka, John M.

AU - Rothschild, Anthony J.

AU - Friedman, Edward S.

AU - Shelton, Richard C.

AU - Keller, Martin B.

AU - Kocsis, James H.

AU - Gelenberg, Alan

PY - 2010/11

Y1 - 2010/11

N2 - Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.

AB - Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.

KW - Maintenance treatment

KW - Major depressive disorder

KW - Psychosocial outcomes

KW - Venlafaxine extended release

UR - http://www.scopus.com/inward/record.url?scp=77957347521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957347521&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2010.04.011

DO - 10.1016/j.jad.2010.04.011

M3 - Article

VL - 126

SP - 420

EP - 429

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -